Otlertuzumab
- Generic Name
- Otlertuzumab
- Drug Type
- Biotech
- CAS Number
- 1372645-37-8
- Unique Ingredient Identifier
- 2MZ3L2664T
- Background
Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Phase 1
Completed
- Conditions
- B-cell Small Lymphocytic Lymphoma Recurrent
- Interventions
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT01317901
- Locations
- 🇺🇸
Site Reference ID/Investigator# 61523, Omaha, Nebraska, United States
🇺🇸Site Reference ID/Investigator# 61542, Augusta, Georgia, United States
🇺🇸Site Reference ID/Investigator# 61522, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath